Oncology

Cancer may be stopped by depriving cells of vital nutrients.

Combination treatment prior to surgery changes the clinical significance of growth factors as potential biomarkers.

Metformin shown to alter metabolic pathways of cancer cells.

Top news of the day from across the health care landscape.

Ductal carcinoma in situ influences risk of all-cause mortality.

A combination of 3 treatments successfully treated a canine with aggressive oral melanoma.

Patient with ductal carcinoma in situ had a lower risk of all-cause mortality compared with the general population.

Availability of new therapies and cost concerns create barriers for cancer patients.

Three studies presented at the European Cancer Congress highlight the need for cancer drug cost reform.

PHLDB3 inhibits the p53 protein to promote tumor growth.

Study estimates 27% of men avoided an unnecessary biopsy for prostate cancer when given an MRI scan first.

Top news of the day from across the health care landscape.

PGAM1 inhibitors sensitize tumors to lynparza (Olaparib) treatment.

Statins degrade mutated p53 proteins, offering future cancer treatment.

Poor long-term survival rates for pediatric patients with acute megakaryoblastic leukemia.

PAN-301-1 is a vaccine candidate to treat patients with persistent prostate cancer.

Top news of the week in oncology and cancer drug development.

Increased use of biosimilars could create sustainable care for multiple chronic diseases.

Utilization of biosimilars has the potential to overhaul cancer treatment.

Cancer cells learn to cope with large scale DNA changes.

Simeprevir was approved by the FDA in late 2013 for hepatitis C virus.

Specialty marketplace continues to thrive going forward.

Methotrexate and cyclophosphamide burn excessive dietary fat.

Aurintricarboxylic acid blocks the spread of glioblastoma.

Plant compound inhibits the metastasis of aggressive breast cancer in mice.

Markers identify patients who benefit from new and more aggressive prostate cancer treatments.

Small cell tumors respond differently to treatment.

Conflicts of interest among committee members who set hepatitis C treatment guidelines may influence decision-making.